argenx SE (ARGX) falls sharply after the company stopped its Phase 3 UNITY trial in Sjögren's disease for futility. The selloff outweighs positive FB102 celiac data, as investors reassess pipeline expansion prospects and the stock's valuation after a major late-stage setback.
argenx SE (ARGX) fell about 14% in after-hours trading after the company discontinued its Phase 3 UNITY trial in Sjögren's disease for futility. The setback reduces one important expansion path for efgartigimod and pressured the stock even as positive FB102 celiac data offered some offset. For investors, the move signals that pipeline risk can still override strong commercial execution and earnings momentum.
argenx SE (ARGX) falls 13.99% to $798.56 in after-hours trading, a sharp reversal from the prior close of $928.44. The immediate catalyst is the decision to stop the Phase 3 UNITY trial in Sjögren's disease for futility, while regular-session trading will confirm whether the extended-hours move holds.
Key Takeaways
ARGX trades at $798.56 in extended hours, down 13.99% from the $928.44 regular-session close.
The main catalyst is argenx's decision to discontinue the Phase 3 UNITY study after an interim analysis showed futility.
Positive Phase 2 FB102 celiac disease data arrived the same day, but it did not offset the late-stage Sjögren's setback.
Strong recent EPS execution and a broad immunology platform support the business, but a $57.74B market value makes pipeline setbacks important.
Why argenx SE (ARGX) Falls After the UNITY Trial Halt
The sharp ARGX decline has a specific clinical cause. On October 8, 2026, argenx announced that it would discontinue the Phase 3 UNITY study of subcutaneous efgartigimod in adults with moderate-to-severe Sjögren's disease.
An Independent Data Monitoring Committee recommended stopping the study for futility after an interim analysis. News coverage said the trial was unlikely to meet its objective, which explains why the stock fell sharply rather than reacting to a routine pipeline update.
This result matters because efgartigimod is the active ingredient behind VYVGART, argenx's flagship FcRn franchise. The halt does not remove VYVGART from its approved uses in generalized myasthenia gravis and immune thrombocytopenia. However, it reduces one path for expanding the drug into another sizable autoimmune market.
The timing also created a difficult contrast. argenx announced positive topline Phase 2 results for FB102 in celiac disease on the same date. The study met its primary endpoint for the change from baseline in the Vh:Cd ratio, with p=0.0176, and argenx plans to advance FB102 into Phase 3. Yet a promising early-stage result usually carries less immediate valuation weight than a late-stage study stopped for futility. Biotech investors tend to reward proof, but they punish lost probability of success with unusual efficiency.
How the UNITY Failure Changes argenx's Pipeline Outlook
The UNITY setback narrows the near-term expansion story for efgartigimod. argenx has built its commercial position around VYVGART and VYVGART HYTRULO, while also developing efgartigimod for additional autoimmune conditions. Sjögren's disease was one of those expansion opportunities, so stopping a Phase 3 study removes a clinical asset from the company's forward pipeline.
Still, the event does not turn argenx into a single-program biotech. The company has cited programs in ocular myasthenia gravis, primary immune thrombocytopenia, myositis, Sjögren's disease, multifocal motor neuropathy, chronic inflammatory demyelinating polyneuropathy, and Graves' disease. It also lists newer assets such as empasiprubart, adimanebart, ARGX-121, ARGX-109, ARGX-118, ARGX-125, and TSP-101.
FB102 adds another layer of diversification. argenx acquired Forte Biosciences in August 2026, and the celiac study marks the first clinical readout after that transaction. The asset targets CD122 and is designed to affect pathogenic T-cell and natural killer cell activity, giving argenx a mechanism beyond FcRn inhibition.
That breadth remains a competitive strength, but breadth alone does not guarantee value. Investors must now assign less value to the Sjögren's opportunity and reassess how much of ARGX's valuation depends on future label expansions. The company still competes from a strong position in FcRn biology, yet large pharmaceutical companies and specialty biotechs also pursue FcRn, complement, B-cell, and other immune-modulating approaches.
argenx Financial Strength and Valuation After the Selloff
The financial backdrop gives ARGX a stronger foundation than a typical development-stage biotech. The stock data lists EPS of 26.24, a P/E ratio of 35.46, and a market capitalization of $57.74B. Those figures show that investors value argenx as a commercial growth company, not merely as a collection of experimental drugs.
Recent earnings history supports that view. On July 23, argenx reported EPS of 7.32 versus an estimate of 6.13, a 19.4% surprise. The company also reported EPS of 5.52 versus 4.92 on May 7 and 8.02 versus 6.24 on February 26. The earnings record shows beats in 6 of the last 7 reported quarters.
The valuation remains demanding enough that pipeline news can move the stock dramatically. ARGX reached a 52-week high of $1,072.75 and a 52-week low of $661.85. The after-hours price sits much closer to the low than the high, signaling a meaningful reset in near-term sentiment, even though the price remains above the year's bottom.
Analyst sentiment before the UNITY announcement leaned positive. UBS upgraded ARGX from Neutral to Buy on August 26, while the analyst dataset lists 31 Buy ratings, 4 Hold ratings, and no Sell ratings. The listed consensus price target is $1,165.29, with a high of $1,415 and a low of $932. Those targets predate the trial halt, so investors should treat them as an earlier view of the pipeline rather than a direct response to the new risk.
What ARGX Investors Should Do After the After-Hours Selloff
The practical takeaway is to separate argenx's commercial franchise from its pipeline optionality. VYVGART and VYVGART HYTRULO remain central to the business, while the UNITY halt directly affects one expansion program. FB102 provides a fresh positive data point, but its Phase 3 path still carries clinical risk because the asset remains earlier in development.
For short-term traders, the $928.44 prior close is the clean reference point. A regular-session recovery above that level would reverse the extended-hours decline, while sustained trading near $798.56 would show that the UNITY news has changed the immediate risk appetite. The first regular session matters because after-hours liquidity can amplify moves.
For long-term investors, the better test is whether the commercial VYVGART franchise and the remaining pipeline justify a 35.46 P/E after one late-stage failure. The stock's strong earnings record argues against treating the company as broken. At the same time, the UNITY outcome proves that even a profitable biotech can lose substantial value when a major expansion opportunity fails.
ARGX's after-hours decline is driven by the concrete loss of the Phase 3 UNITY opportunity, not by a broad earnings collapse. The positive FB102 result and strong recent EPS history keep the long-term case alive, but investors now need to value argenx around its proven commercial franchise rather than assume every pipeline program will succeed.
ARGX fell after argenx said it would stop the Phase 3 UNITY trial in Sjögren's disease because an interim analysis showed futility. That late-stage setback outweighed the company's positive FB102 celiac disease data.
+Should I buy ARGX stock now?
The stock may appeal to long-term investors who believe in argenx's commercial VYVGART franchise and broader pipeline, but the UNITY failure adds real near-term risk. A cautious approach is warranted until the market digests the trial halt and the stock finds a stable level.
+What caused argenx to fall after hours?
The immediate catalyst was the decision to discontinue the Phase 3 UNITY study of efgartigimod in Sjögren's disease for futility. After-hours trading reacted sharply because the trial had been a meaningful pipeline expansion opportunity.
+Does the UNITY trial halt hurt argenx's long-term outlook?
It hurts the company's growth optionality by removing one potential indication for efgartigimod, but it does not damage the approved VYVGART franchise. argenx still has a diversified pipeline and strong earnings history, so the long-term story remains intact, though less certain.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on ARGX?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
